There is no way Theseus Pharmaceuticals Inc. (THRX) can keep these numbers up

Theseus Pharmaceuticals Inc. (NASDAQ: THRX) stock fell -0.45% on Monday to $11.00 against a previous-day closing price of $11.05. With 2.55 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.18 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $11.55 whereas the lowest price it dropped to was $10.31. The 52-week range on THRX shows that it touched its highest point at $15.21 and its lowest point at $4.01 during that stretch. It currently has a 1-year price target of $21.67.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of THRX was up-trending over the past week, with a rise of 14.58%, but this was up by 104.08% over a month. Three-month performance surged to 85.19% while six-month performance rose 67.17%. The stock gained 11.00% in the past year, while it has gained 120.88% so far this year. A look at the trailing 12-month EPS for THRX yields -1.17 with Next year EPS estimates of -1.99. For the next quarter, that number is -0.44. This implies an EPS growth rate of -120.70% for this year and -40.10% for next year.

Float and Shares Shorts:

At present, 38.59 million THRX shares are outstanding with a float of 38.11 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.94 million, which was 2.44% higher than short shares on Sep 14, 2022. In addition to Dr. Iain D. Dukes D.Phil., DPHIL, M.A. as the firm’s Co-Founder & Chairman, Dr. Timothy P. Clackson Ph.D. serves as its CEO, Pres & Director.


Institutional Ownership:

Through their ownership of 89.68% of THRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 17.36% of THRX, in contrast to 11.24% held by mutual funds. Shares owned by individuals account for 105.87%. As the largest shareholder in THRX with 12.41% of the stake, Fidelity Management & Research Co holds 4,802,535 shares worth 4,802,535. A second-largest stockholder of THRX, T. Rowe Price Associates, Inc., holds 1,381,489 shares, controlling over 3.57% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in THRX, holding 676,035 shares or 1.75% stake. With a 4.80% stake in THRX, the Fidelity Select Port. – Biotechno is the largest stakeholder. A total of 1,857,891 shares are owned by the mutual fund manager. The T Rowe Price Health Sciences Fund, which owns about 2.61% of THRX stock, is the second-largest Mutual Fund holder. It holds 1,009,115 shares valued at 5.03 million. Fidelity Select Port. – Health Ca holds 1.55% of the stake in THRX, owning 600,000 shares worth 2.99 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for THRX since 6 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With THRX analysts setting a high price target of $24.00 and a low target of $18.00, the average target price over the next 12 months is $21.67. Based on these targets, THRX could surge 118.18% to reach the target high and rise by 63.64% to reach the target low. Reaching the average price target will result in a growth of 97.0% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. THRX will report FY 2022 earnings on 03/07/2024. Analysts have provided yearly estimates in a range of -$1.14 being high and -$1.46 being low. For THRX, this leads to a yearly average estimate of -$1.37. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Theseus Pharmaceuticals Inc. surprised analysts by -$0.05 when it reported -$0.38 EPS against a consensus estimate of -$0.33. The surprise factor in the prior quarter was -$0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.41 and the low estimate is -$0.47. The average estimate for the next quarter is thus -$0.43.

Summary of Insider Activity:

Insiders traded THRX stock several times over the past three months with 6 Buys and 0 Sells. In these transactions, 398,002 shares were bought while 0 shares were sold. The number of buy transactions has increased to 6 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 398,002 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *